Premium
Gelatin‐coated Gold Nanoparticles as Carriers of FLT 3 Inhibitors for Acute Myeloid Leukemia Treatment
Author(s) -
Suarasan Sorina,
Simon Timea,
Boca Sanda,
Tomuleasa Ciprian,
Astilean Simion
Publication year - 2016
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12725
Subject(s) - myeloid leukemia , gelatin , sorafenib , midostaurin , colloidal gold , in vivo , drug , leukemia , chemistry , pharmacology , in vitro , cancer research , nanoparticle , drug delivery , nanomedicine , materials science , nanotechnology , medicine , immunology , biochemistry , biology , microbiology and biotechnology , hepatocellular carcinoma
This study presents the design of a gold nanoparticle (Au NP s)—drug system with improved efficiency for the treatment of acute myeloid leukemia. The system is based on four different FLT 3 inhibitors, namely midostaurin, sorafenib, lestaurtinib, and quizartinib, which were independently loaded onto gelatin‐coated gold nanoparticles. Detailed investigation of the physicochemical properties of the formed complexes lead to the selection of quizartinib—loaded Au NP s for the in vitro evaluation of the biological effects of the formed complex against OCI ‐ AML 3 acute myeloid leukemia cells. Viability tests by MTT demonstrated that the proposed drug complex has improved efficacy when compared with the drug alone. The obtained results constitute a premise for further in vivo investigation of such drug vehicles based on Au NP s. To the best of our knowledge, this is the first study that investigates the delivery of the above‐mentioned FLT 3 inhibitors via gelatin‐coated gold nanoparticles.